A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)

被引：0
|
作者：
Choueiri, T. K. [1 ]
Escudier, B. [2 ]
Powles, T. [3 ]
Cella, D. [4 ]
Lee, Y. [5 ]
Laird, D. A. [5 ]
Scheffold, C. [5 ]
Motzer, R. J. [6 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[3] Queen Mary Univ, Barts Canc Inst, London, England
[4] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Exelixis Inc, San Francisco, CA USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
BJU INTERNATIONAL | 2013年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
7
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [1] Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with dear cell renal cell carcinoma (METEOR)
    Choueiri, Toni K.
    Escudier, Bernard J.
    Les, Thomas Pow
    Cella, David
    Ru, Qinhua C.
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] A phase I study of cabozantinib (XL184) in patients with renal cell cancer
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. F.
    Morrissey, S.
    Ferguson, K. C.
    Holland, J.
    Kaelin, W. G.
    Dutcher, J. P.
    ANNALS OF ONCOLOGY, 2014, 25 (08) : 1603 - 1608
  • [3] Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Pal, Sumanta Kumar
    McDermott, David F.
    Ramies, David A.
    Morrissey, Stephanie
    Lee, Yihua
    Miles, Dale
    Holland, Jaymes S.
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [4] Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)
    Choueiri, Toni K.
    Pal, Sumanta Kumar
    McDermott, David F.
    Ramies, David A.
    Morrissey, Stephanie
    Lee, Yihua
    Miles, Dale
    Holland, Jaymes
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial
    Choueiri, T.
    Escudier, B.
    Powles, T.
    Mainwaring, P.
    Rini, B.
    Donskov, F.
    Hammers, H.
    Hutson, T.
    Roth, B.
    Peltola, K.
    Lee, J. L.
    Heng, D.
    Schmidinger, M.
    Borgman-Hagey, A.
    Hessel, C.
    Scheffold, C.
    Schwab, G.
    Tannir, N.
    Motzer, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S709
  • [6] Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
    Thomas Powles
    Toni K. Choueiri
    Robert J. Motzer
    Eric Jonasch
    Sumanta Pal
    Nizar M. Tannir
    Sabina Signoretti
    Rajesh Kaldate
    Christian Scheffold
    Evelyn Wang
    Dana T. Aftab
    Bernard Escudier
    Daniel J. George
    BMC Cancer, 21
  • [7] Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study
    Bracarda, S.
    Choueiri, T. K.
    Powles, T.
    Motzer, R. J.
    Olencki, T.
    Frontera, O. A.
    Oudard, S.
    Rolland, F.
    Tomczak, P.
    Castellano, D.
    Appleman, L.
    Drabkin, H.
    Vaena, D.
    Milwee, S.
    Youkstetter, J.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S196 - S196
  • [8] Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)
    Schmidinger, M.
    Motzer, R. J.
    Powles, T.
    Escudier, B.
    Tannir, N. M.
    Mainwaring, P. N.
    Rini, B. I.
    Hammers, H. J.
    Donscov, F.
    Roth, B.
    Peltola, K.
    Lee, J. L.
    Heng, D. Y. C.
    Aftab, D. T.
    Hessel, C.
    Scheffold, C.
    Schwab, G.
    Pal, S.
    Hutson, T. E.
    Choueiri, T. K.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S187 - S188
  • [9] Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
    Cella, D.
    Escudier, B.
    Tannir, N.
    Powles, T.
    Donskov, F.
    Peltola, K.
    Schmidinger, M.
    Heng, D.
    Mainwaring, P.
    Hammers, H.
    Lee, J-L.
    Rini, B. I.
    Roth, B.
    Baer, J.
    Mangeshkar, M.
    Scheffold, C.
    Hutson, T.
    Pal, S.
    Motzer, J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma
    Apolo, Andrea Borghese
    Parnes, Howard L.
    Madan, Ravi Amrit
    Gulley, James L.
    Wright, John Joseph
    Khadar, Kattie
    Trepel, Jane B.
    Schlom, Jeffrey
    Arlen, Philip M.
    Merino, Maria
    Steinberg, Seth M.
    Choyke, Peter L.
    Lindenberg, Maria Liza
    Kurdziel, Karen A.
    Folio, Les
    Figg, William Douglas
    Agarwal, Piyush K.
    Bottaro, Donald P.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345